EPIX
ESSA Pharma Inc
$
1.880
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.880
Open
1.870
VWAP
1.87
Vol
185.58K
Mkt Cap
83.45M
Low
1.870
Amount
347.03K
EV/EBITDA(TTM)
--
Total Shares
44.36M
EV
-30.42M
EV/OCF(TTM)
--
P/S(TTM)
--
ESSA Pharma Inc. is a Canada-based pharmaceutical company that was previously focused on developing therapies for the treatment of patients with prostate cancer. The Company is undergoing a comprehensive review process to review its strategic options to maximize shareholder value.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
--
--
-0.040
-79.04%
--
--
-0.160
+14.88%
--
--
-0.170
+5.83%
Estimates Revision
The market is revising No Change the revenue expectations for ESSA Pharma Inc. (EPIX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 5.03%.
EPS Estimates for FY2025
Revise Upward
+0.25%
In Past 3 Month
Stock Price
Go Up
+5.03%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for ESSA Pharma Inc (EPIX.O) is -2.97, compared to its 5-year average forward P/E of -7.35. For a more detailed relative valuation and DCF analysis to assess ESSA Pharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-7.35
Current PE
-2.97
Overvalued PE
-1.28
Undervalued PE
-13.42
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.54
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.77
Undervalued EV/EBITDA
-11.85
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.83
Current PS
0.00
Overvalued PS
6.67
Undervalued PS
-5.01
Financials
Annual
Quarterly
FY2025Q2
YoY :
-29.65%
-7.38M
Operating Profit
FY2025Q2
YoY :
-29.09%
-6.37M
Net Income after Tax
FY2025Q2
YoY :
-30.00%
-0.14
EPS - Diluted
FY2025Q2
YoY :
+0.45%
-6.85M
Free Cash Flow
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 287078.23% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
12.0M
USD
1
0-12
Months
20.9K
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 13851.93% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
4.2M
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 287078.23% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
12.0M
USD
1
0-12
Months
20.9K
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
EPIX News & Events
Events Timeline
2025-07-14 (ET)
2025-07-14
08:03:59
XenoTherapeutics to acquire Essa Pharma
2025-02-11 (ET)
2025-02-11
06:08:22
Essa Pharma reports Q4 EPS (19c) vs. (14c) last year
2024-12-17 (ET)
2024-12-17
06:04:59
Essa Pharma reports Q4 EPS (14c), consensus (27c)
Sign Up For More Events
Sign Up For More Events
News
8.5
07-23PRnewswireESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to Shareholders
7.0
07-19GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BGSF, EPIX, BLBX, PBBK on Behalf of Shareholders
7.0
07-14PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DALN, RGLD, EPIX on Behalf of Shareholders
Sign Up For More News
People Also Watch
OKUR
Onkure Therapeutics Inc
2.310
USD
-2.53%
IPSC
Century Therapeutics Inc
0.626
USD
-5.15%
CTM
Castellum Inc
1.320
USD
+4.76%
LSBK
Lake Shore Bancorp Inc
12.150
USD
+0.41%
CVGI
Commercial Vehicle Group Inc
1.970
USD
+4.79%
GALT
Galectin Therapeutics Inc
2.910
USD
-1.02%
HOUR
Hour Loop Inc
1.880
USD
+2.73%
ANIX
Anixa Biosciences Inc
3.220
USD
-4.45%
WLGS
WANG & LEE GROUP Inc
0.093
USD
+6.92%
CATO
Cato Corp
3.040
USD
-4.10%
FAQ
What is ESSA Pharma Inc (EPIX) stock price today?
The current price of EPIX is 1.88 USD — it has increased 0.53 % in the last trading day.
What is ESSA Pharma Inc (EPIX)'s business?
What is the price predicton of EPIX Stock?
What is ESSA Pharma Inc (EPIX)'s revenue for the last quarter?
What is ESSA Pharma Inc (EPIX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for ESSA Pharma Inc (EPIX)'s fundamentals?
How many employees does ESSA Pharma Inc (EPIX). have?